XML 50 R29.htm IDEA: XBRL DOCUMENT v3.23.2
Development and Other Agreements (Details) - Verily Life Sciences - Collaborative Arrangement - USD ($)
$ / shares in Units, $ in Millions
3 Months Ended 12 Months Ended
Dec. 31, 2021
Dec. 31, 2018
Dec. 31, 2019
Dec. 31, 2022
Mar. 31, 2022
Dec. 28, 2018
Nov. 30, 2018
Other Commitments [Line Items]              
Amortization period       64 months      
Initial Payment              
Other Commitments [Line Items]              
Closing stock price (USD per share)           $ 29.57  
Initial payment on collaborative agreement   $ 250.0          
Issuance of common stock in connection with acquisition, shares (shares)   7,363,772          
Collaborative research and development fee $ 87.1 $ 217.7          
Milestone Payments              
Other Commitments [Line Items]              
Collaborative research and development fee     $ 3.2        
Potential future common stock issuable (shares)             5,154,640
Sales-based milestones       $ 152.4      
Approval Milestone              
Other Commitments [Line Items]              
Potential future common stock issuable (shares)         2,945,508